

**Date: August 12, 2025**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir,

**Sub: Press Release to the Analysts/Investors**

We refer to the unaudited financial results for the first quarter of the FY 2025-2026, submitted to you today, i.e., on August 12, 2025. We are now enclosing the press release in this regard to the Analysts/Investors, which is also being uploaded on our website.

This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

**For GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**



**REGISTERED OFFICE**

**Granules India Limited**

CIN: L24110TG1991PLC012471

15<sup>th</sup> Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India

Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

[www.granulesindia.com](http://www.granulesindia.com)

**Press Release**

**for Immediate Release**

**Q1FY26 Revenue from operations at INR 12,101 Mn up 3% YoY, EBITDA (before exceptional items) at INR 2,467 Mn down 5% YoY, PBT (before exceptional items) at INR 1,704 Mn down 6% YoY, PAT (after exceptional items) at INR 1,126 Mn down 16% YoY.**

**Hyderabad, India, August 12, 2025:** Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended June 30, 2025.

### **Financial Summary (All numbers in INR Mn)**

QUARTERLY CONSOLIDATED FINANCIALS	Q1FY26	Q4FY25	Growth (QoQ)	Q1FY25	Growth (YoY)
Revenue from Operations	12,101	11,974	1%	11,799	3%
EBITDA before exceptional items	2,467	2,524	(2%)	2,593	(5%)
EBITDA %	20%	21%		22%	
PBT before exceptional items	1,704	1,668	2%	1,814	(6%)
PAT	1,126	1,520	(26%)	1,346	(16%)
PAT %	9%	13%		11%	

### **Financial and Business Summary for Q1FY26**

- Q1FY26 includes Financials of Senn Chemicals AG.
- Revenue from Operations of Q1FY26 stood at INR 12,101 Mn, a growth of 3% YoY, Sales growth was largely driven by North America.
- Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), Finished dosages (FD) and Peptides/ CDMO contribute 14%, 10%, 74% and 2% of revenue from operations respectively for Q1FY26.
- ROCE is at 16.0% (Post Acquisition of Senn Chemicals AG) as compared to 16.6% YoY.
- Net debt stood at INR 9,480 Mn and Net debt to EBITDA at 0.96x.

**Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said,** “We delivered healthy cash flow from operations of ₹2,806 million this quarter and made good progress on the Gagillapur remediation program. USFDA audits at our Bonthapally API facility, GPI in Virginia, and Granules Life Sciences at Genome Valley were successfully completed with one minor observation each. The Danish Medicines Agency also concluded its EU GMP inspection of Gagillapur with certification granted. With our near-term formulations growth trajectory set to resume, and the integration of Senn Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned for sustainable long-term growth”

### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

### **Safe Harbor**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*

<b>Contacts:</b>	
<b>Granules IR Desk</b> investorrelations@granulesindia.com	<b>Chaitanya Tummala</b> Company Secretary chaitanya.tummala@granulesindia.com